cas 2621932-48-5|| where to buy 2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Produktname:2-(8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

IUPAC Name:2-[8-ethyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM1013587-1g	in stock	ƴȤƐ
CM1013587-5g	in stock	ǆȤƐƚ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2621932-48-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2621932-48-5; Molekulare Formel:C20H26BFO4; Schmelzpunkt:-; SMILES-Code:CCC1=C(F)C=CC2=CC(OCOC)=CC(B3OC(C)(C)C(C)(C)O3)=C12; Dichte:

: Katalognummer:CM1013587; Molekulargewicht:360.23; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Boronic Acids and Esters; Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).; Boronic Acid For Sale; Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

: HRS-4642; HRS-4642 is a high affinity, selective, long-acting, and non-covalent KRAS G12D inhibitor, with an affinity constant of 0.083 nM. HRS-4642 demonstrated robust efficacy against KRAS G12D-mutant cancers both in vitro and in vivo. Importantly, in a phase 1 clinical trial, HRS-4642 exhibited promising anti-tumor activity in the escalating dosing cohorts. Furthermore, the sensitization and resistance spectrum for HRS-4642 was deciphered through genome-wide CRISPR-Cas9 screening, which unveiled proteasome as a sensitization target. HRS-4642, either as a single agent or in combination with carfilzomib, reshaped the tumor microenvironment toward an immune-permissive one.